Evidence map›Paper›PMID 40102306›Full record

ArticleAnnals of hematology2025

Effect of major ABO blood group mismatched HSCT on blood transfusion and clinical outcomes in AA patients.

Dongdi Lai, Dandan Chen, Xiaowei Chen, Ruiqing Zhou, Minglu Zhong, Xiaojie Chen, Jianyun Huang, Yanfei Lan, Xinxin Tong, Zhen Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dongdi LaiDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Dandan ChenDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Xiaowei ChenDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Ruiqing ZhouDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Minglu ZhongDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Xiaojie ChenDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Jianyun HuangDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Yanfei LanDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Xinxin TongDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Zhen LiuDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Xuexin YangDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China.
Shunqing WangDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China. shqwang_cn@163.com.
Yaming WeiDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China. eywym@scut.edu.cn.
Zhaohu YuanDepartment of Blood Transfusion, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, 510180, China. eyyuanzhaohu@scut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the impact of the ABO blood group major match type on stem cell engraftment, blood transfusion and clinical outcomes in aplastic anemia patients with hematopoietic stem cell transplantation (HSCT), we retrospectively analyzed the data of 361 aplastic anemia patients treated with HSCT, and found ABO major mismatched resulted in delayed red blood cells (RBCs) engraftment and ABO blood group conversion. The patients in the ABO major mismatched group required more units of RBCs and PLTs transfusions. Multivariate linear regression analysis showed that ABO mismatched, acute graft-versus-host disease (aGVHD), time to RBCs and PLTs engraftment and blood group conversion, and baseline hemoglobin were significantly associated with RBCs transfusion, the factors associated with PLTs transfusion were the PLTs, RBCs and neutrophils engraftment, graft rejection, baseline PLTs, aGVHD grade II-IV, and severe chronic GVHD. Multivariate analysis showed that the time to neutrophils engraftment, baseline hemoglobin, and aGVHD were independent poor prognostic factors to both overall survival and failure-free survival. Moreover, the major ABO-mismatched HSCT group were hospitalized more often. These findings suggest that it's better to select a donor with an ABO major match to reduce the burden of transfusion and the impact of hospitalization, if conditions permit.

Indexed as

ABO Blood-Group SystemAnemia, AplasticBlood Group IncompatibilityBlood TransfusionHematopoietic Stem Cell TransplantationAdolescentAdultChildChild, PreschoolFemaleGraft vs Host DiseaseHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeABO Blood-Group SystemABO blood groupAplastic anemiaHematopoietic stem cell transplantationMajor mismatched transplantationSurvival analysisTransfusion

Identifiers

PMID40102306
PMCPMC12031907

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.